French pharma major Sanofi (Euronext: SAN) is to stop producing TheraCys/ImmuCyst (Bacillus Calmette-Guerin), its vaccine for non-muscle invasive bladder cancer.
The company’s vaccines unit, Sanofi Pasteur, made the announcement on Friday after failed attempts to guarantee the long-term availability of the product, which is commonly known as BCG.
These efforts included identifying companies with an interest in taking on BCG, but none would commit to the project and so Sanofi has chosen to cease production of the vaccine in mid-2017.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze